Vioxx Side Effects Celebrex Side Effects

Vioxx Legal Saga - insurers don?t want to pay for the company?s defense against the lawsuits.
As the number of Vioxx-related cases mounts, Merck (MRK:NYSE) is discovering that some of its insurers don't want to pay for the company's defense against the lawsuits. Merck says it will fight the insurers' efforts to reduce or eliminate coverage. Merck Updates Vioxx Legal Saga By Robert Steyer TheStreet.com Staff Reporter 3/14/2005 11:36 AM ...

FDA Celebrex, Bextra and Vioxx panelists had industry ties
Ten of the 32 government drug advisers who last week endorsed continued marketing of the huge-selling pain pills Celebrex, Bextra and Vioxx have consulted in recent years for the drugs' makers, according to disclosures in medical journals and other public records. If the 10 advisers had not cast their votes, ...

VIOXX Lawyer Examines Fen-Phen Settlement and Finds a Mass Tort Mess
The American Lawyer Examines Fen-Phen Settlement and Finds a Mass Tort Mess, The American Lawyer(R) reports that the fen-phen class action, approved in 2000 and once expected to represent a model for resolving mass torts equitably, has instead become a prescription for alleged legal and medical fraud. Expected settlement costs ...

Gov?t OKs Vioxx, Celebrex, Bextra
A Food and Drug Administration advisory panel narrowly voted Friday to recommend that Merck & Co. be allowed to resume sales of its painkiller Vioxx, which the company removed from the market last year because it increased patients' risk of cardiovascular problems. The panel said that all three scrutinized ...

FDA Panel: Celebrex Should Stay on Market
Advisers to the Food and Drug Administration concluded Friday the popular painkiller Celebrex poses an increased risk for heart problems but should remain on the market because the benefits outweigh the dangers. The panelists suggested a number of possible restrictions, including placing a "black box" warning on the label warning ...

Vioxx Fans Have Their Say
Patients who rely on painkillers like Bextra and Celebrex are seeking more relief. They long for a day when they no longer have to worry that their medications will be pulled from the market. One after another, pain sufferers -- most with arthritis -- pleaded Thursday with government advisers to ...

Merck: Other Vioxx-Like (COX-2 inhibitors)Drugs Hurt Heart
The heart attack and stroke risks linked to withdrawn arthritis drug Vioxx are an inherent problem for similar pain pills, Vioxx maker Merck & Co. Inc. (NYSE:MRK - news) told advisers to the U.S. Food and Drug Administration (news - web sites) on Wednesday. Merck voluntarily withdrew Vioxx ...

Merck?s Actions on Vioxx Face New Scrutiny
The spotlight is likely to be on Pfizer tomorrow when federal drug regulators begin hearings on cox-2 drugs, the class of arthritis and pain medicines that include the company's Celebrex and Bextra brands. After all, Merck, which made the other drug in that class, Vioxx, pulled it off the market ...

Banned Lancet Report on Vioxx Published
The report was accepted by the Lancet last year and scheduled for publication in November, about the same time that Graham was to testify to a Senate committee about the study's findings. "On Nov. 16, I was ordered to withdraw the paper or 'face severe consequences' — which I interpreted ...

Cox-2 Woes Fuel Drug Ad Debate
Direct-to-consumer advertising of the cox-2 prescription painkillers Vioxx and Celebrex helped catapault worldwide sales of the drugs into the billions. Now, with Vioxx pulled off the market by its maker and Celebrex's future uncertain, some experts say direct-to-consumer (DTC) advertising of these and other prescription drugs focuses far too heavily ...